medigraphic.com
ISSN 1560-4381 (Print)

2014, Number 4

<< Back

Correo Científico Médico 2014; 18 (4)

Presentation of a Patient with Stevens-Johnson syndrome and toxic epidermal necrolysis

Cedeño MA, Márquez CJE, Tamayo SJR

Language: Spanish
References: 15
Page: 793-799
PDF size: 360.01 Kb.


ABSTRACT

Six years old, mixed race school girl patient, with a health record, no family history to note, was presented. Born from a normal pregnancy and a delivery at term. Properly fed, well immunized. Good growth and development. The patient had come to her family physician because of cold symptoms with persistent cough and fever; she received a medication with phenytoin among other drugs. On the second day of treatment the patient developed cutaneous manifestations of blisters that exposed, when opened, erythematous and humid areas that extended to almost the entire body surface. The Stevens - Johnson syndrome is a potentially fatal skin disease characterized by extensive epidermal and mucosal necrosis that is accompanied by malaise. Stevens Johnson Syndrome and toxic epidermal necrolysis are hypersensitivity reactions that are considered clinic and pathologic entity of the same polar forms. Both Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are severe cutaneous adverse reactions associated with some medications (RACS). These conditions have significant impact on public health because of its high morbidity and mortality. The percentage of affected skin surface classifies this disease into three groups and could define the prognosis: -SSJ, when it affects less than 10% body surface - Overlapping SSJ-NET of 10-30% - NET, greater than 30% skin detachment.


REFERENCES

  1. Sotelo Cruz N. Síndrome de Stevens-Johnson y necrólisis epidérmica tóxica en los niños. Gaceta Méd México. 2012 [citado 11 sep 2014]; 148:265-75. Disponible en: http://www.medigraphic.com/pdfs/gaceta/gm-2012/gm123h.pdf

  2. Vanessa N, Oakley A. Smith.Stevens Johnson Syndrome & Toxic Epidermal Necrolysis. Dermnet NZ. 2014 [citado 11 sep 2014]; 29. Disponible en: http://dermnetnz.org/reactions/sjs-ten.html

  3. Fujita Y, Yoshioka N, Abe R. Rapid Immunochromatographic Test for Serum Granulysin Is Useful for the Prediction of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. J Am Acad Dermatol.2014 [citado 11 sep 2014]; 65:65-68. Disponible en: http://www.jaad.org/article/S0190-9622(13)00509-4/references

  4. Fernando SL. The management of toxic epidermal necrolysis.Aust J of Dermatol. 2012 [citado 11 sep 2014]; 53: 165-71. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/22881464

  5. Klein PA, Elston DM. Dermatologic Manifestations of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. J Am Acad Dermatol. 2013 [citado 11 sep 2014]23. Disponible en:http://emedicine.medscape.com/article/1124127-overview

  6. Organización Mundial de la Salud. Medicamentos: seguridad y reacciones adversas. En: Seguridad en el uso de medicamentos en Atención Primaria. Programa de mejora de la seguridad en la prescripción de medicamentos de la SESCAM. España: OPS; 2012. [citado 11 sep 2014]Disponible: http://www.seguridadpaciente.com/2012/docs/ponen/p5.pdf

  7. Fernández Busso N. Los efectos adversos y la calidad de atención. Estrategias para mejorar la seguridad de los pacientes pediátricos.2004 [citado 11 sep 2014] Arch argent Pediatr; 102 (5): 402-410. Disponible en: http://www.scielo.org.ar/pdf/aap/v102n5/v102n5a14.pdf

  8. Gutiérrez S, Repetto M. Episodios adversos a medicamentos, detectados en dos servicios de internación pediátrica del Centro Hospitalario Pereira Rossell.2004 [citado 11 sep 2014] Arch Pediatr Urug; 75 (4): 307-315. Disponible en: http://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2005/p20503

  9. Kuhn Córdova I, Ramírez Bouchan D, Gamboa Marrufo JD. Uso de inmunoglobulina intravenosa en el tratamiento de Necrólisis epidérmica tóxica y síndrome de Stevens- Johnson. 2007 [citado 11 sep 2014] An Pediatr Barc; 67(1): 68-73. Disponible en: http://bvsalud.org/portal/resource/pt/ibc-055331

  10. Crosi A, Borges González S, Estévez Carrizo F. Reacciones adversas medicamentosas graves: síndrome de Stevens-Johnson y Necrólisis epidérmica tóxica. Rev Med Uruguay 2004 [citado 11 sep 2014]; 20: 172-177. Disponible en: http://www.rmu.org.uy/revista/20/3/2/es/2/resumen/

  11. Telechea H, Speranza N, Giachetto G, Pírez MC. Síndrome de Stevens Johnson: una enfermedad habitualmente producida por medicamentos. Arch Pediatr Urug. 2008 [citado 11 sep 2014]; 79 (3): 229-234. Disponible en: www.um.edu.uy/docs/stevend_johnson.pdf

  12. Álvarez Luna JF, Gómez Vázquez M, Moreno González AL, Melchor Hernández A, Escamilla Acosta MA, Romo Hernández G. Erythroderma caused by vancomycin in children: concentration and speed of infusion. Univ Aut Estado Hidalgo. 2010 [citado 11 sep 2014]; 2.Disponible en: http://www.uaeh.edu.mx/scige/revista/icsa/n2/a5.html

  13. Clavijo R, D´Avila I, Garcia MJ. Síndrome de Stevens Johnson: una forma grave de las reacciones adversas a medicamentos. BIOMEDICINA.2011 [citado 11 sep 2014]; 6 (3):26 – 34. Disponible en: http://www.um.edu.uy/docs/stevend_johnson.pdf

  14. Schwartz RA, McDonough PH, Lee BW; Toxic epidermal necrolysis: Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol.2013 [citado 11 sep 2014]; 69(2):173. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/23866878

  15. Wright M, Harding M, Payne J. Toxic Epidermal Necrolysis. Hautarz.2014 [citado 11 sep 2014]; 57(11): 1016-8.Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/?term=Gynecomastia+Toxic+Epidermal+Necrolysis




2020     |     www.medigraphic.com